Clinical Trials Logo

Clinical Trial Summary

Randomized, double-blind, placebo-controlled, dose escalation study. There will be 3 cohorts of patients defined by the antigen dose (10, 30 or 100 µg of each antigen), and within each cohort, patients will be randomized at a ratio of 3:1:1 to one of the following:

1. GEN-003/M2: GEN-003 plus Matrix M-2 adjuvant (50 µg per dose)

2. GEN-003: Antigens alone

3. Placebo (DPBS diluent)

Each Cohort is divided into 2 Groups. For each dose cohort, immunizations begin with a Pilot Group. Immunization of the remainder of the Group "Continuation Group") is contingent upon successful review of data from the Pilot Group through Day 7 after immunization. Dose escalation to the next dose level Cohort proceeds after evaluation of safety data from all patients in the prior Cohort and only after all specified safety criteria are met. The total numbers of patients in each Group and Cohort are as follows:

- 10 µg Cohort: 10 Pilot Group, 40 Continuation Group (50 Total)

- 30 µg Cohort: 10 Pilot Group, 40 Continuation Group (50 Total)

- 100 µg Cohort: 10 Pilot Group, 40 Continuation Group (50 Total)

- Totals per group: 30 Pilot Group, 120 Continuation Group (150 Total Patients)

Subjects will receive 3 doses of the assigned treatment (GEN-003/M-2, GEN-003, or placebo) at 3 week intervals. Sampling from mucocutaneous genital sites for viral shedding will be done twice daily for 28 days prior to the first immunization (baseline shedding), and again following the last immunization. Follow-up for safety monitoring will be conducted for 12 months after the last immunization.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01667341
Study type Interventional
Source Genocea Biosciences, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 2012
Completion date May 9, 2014

See also
  Status Clinical Trial Phase
Completed NCT02910284 - Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity N/A
Completed NCT02515175 - Evaluating New Formulation of Therapeutic HSV-2 Vaccine Phase 2
Completed NCT02114060 - Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine Phase 2
Completed NCT02300142 - Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study Phase 2
Recruiting NCT05432583 - A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions Phase 1
Completed NCT02030301 - Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults Phase 1/Phase 2